Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.
作者： Etienne Chatelut , Dirk Jan A. R. Moes , Jennifer Martin , Jeroen J. M. A. Hendrikx , Joseph Ciccolini
DOI: 10.1002/PRP2.757
关键词:
摘要: Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these poses the usual question field of onco-hematology: individual dosing and potential therapeutic drug monitoring (TDM) to carry out this individualization. However, Mabs present unique pharmacological characteristics for TDM, pharmacokinetic-pharmacodynamic relationship observed should be interpreted differently than conventional small molecules. This pharmacology practice review has been summarized a public debate between authors at International TDM Clinical Toxicology meeting Banff, 2020, regarding roles Mab/ICI setting.
sci-hub.st 参考文章(58)
Diane R. Mould, Bruce Green, Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs. ,vol. 24, pp. 23- 39 ,(2010) , 10.2165/11530560-000000000-00000
Steven R. Alberts, Joleen M. Hubbard, Alternate dosing of cetuximab for patients with metastatic colorectal cancer Gastrointestinal cancer research : GCR. ,vol. 6, pp. 47- 55 ,(2013)
Gilles Freyer, Bakrin, Hamizi, Henin, Mohtaram, Le Saux, Falandry, Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. OncoTargets and Therapy. ,vol. 6, pp. 89- 94 ,(2013) , 10.2147/OTT.S27733
TH Oude Munnink, MJ Henstra, LI Segerink, KLL Movig, P Brummelhuis-Visser, Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology Clinical Pharmacology & Therapeutics. ,vol. 99, pp. 419- 431 ,(2016) , 10.1002/CPT.211
E Chatelut, M L White-Koning, R HJ Mathijssen, F Puisset, S D Baker, A Sparreboom, Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. British Journal of Cancer. ,vol. 107, pp. 1100- 1106 ,(2012) , 10.1038/BJC.2012.357
Amit Garg, Joseph P. Balthasar, Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 34, pp. 687- 709 ,(2007) , 10.1007/S10928-007-9065-1
Shuang Bai, Karin Jorga, Yan Xin, Denise Jin, Yanan Zheng, Lisa A. Damico-Beyer, Manish Gupta, Meina Tang, David E. Allison, Dan Lu, Yi Zhang, Amita Joshi, Mark J. Dresser, A guide to rational dosing of monoclonal antibodies. Clinical Pharmacokinectics. ,vol. 51, pp. 119- 135 ,(2012) , 10.2165/11596370-000000000-00000
Diane D. Wang, Shuzhong Zhang, Hong Zhao, Angela Y. Men, Kourosh Parivar, Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. The Journal of Clinical Pharmacology. ,vol. 49, pp. 1012- 1024 ,(2009) , 10.1177/0091270009337512
Chee M. Ng, Bert L. Lum, Veronica Gimenez, Steve Kelsey, David Allison, Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis Pharmaceutical Research. ,vol. 23, pp. 1275- 1284 ,(2006) , 10.1007/S11095-006-0205-X
Vivian W. Ng, Michaela Lehle, Bert L. Lum, Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemotherapy and Pharmacology. ,vol. 73, pp. 737- 747 ,(2014) , 10.1007/S00280-014-2400-5